Use of statins and nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with decreased mortality in men with prostate cancer, new findings suggest.
The findings are based on a study of 7,042 men who underwent radical prostatectomy (RP) or radiotherapy (RT) for prostate cancer between 1990 and 2003. Matthew S. Katz, MD, of the Department of Radiation Oncology at Saints Medical Center in Lowell, Mass., and collaborators identified these men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a primarily community-based national prostate cancer registry. The median follow-up after treatment was four years.
In the 4,611 men who had RP, patients who had ever used statins had a 65% reduced risk of all-cause mortality compared with men who never used the medications, according to a report in BJU International (2010; published online ahead of print). In the 2,431 men treated with RT, statin users had a 41% decreased risk compared with those who never used statins. NSAID ever-use was associated with a 53% decreased risk of all-cause mortality in the RP group and 61% decreased risk in the RT group.
“Doctors and patients should focus on other health issues after curative treatment, as the prostate cancer-specific mortality rate is much lower than death from other causes,” the authors wrote. “Our retrospective findings support the health benefits of statins and NSAIDs after curative cancer treatment.”
Dr. Katz’s group provided causes of death for 389 RP patients and 487 RT patients. In these groups, 21% and 20%, respectively, died from prostate cancer, 21% and 30% died from cardiovascular disease, and 25% and 13% died from other cancers.